Department of Traditional Chinese Medicine, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
Department of Physiology, Shenzhen University Health Science Center, Shenzhen University, Shenzhen 518060, Guangdong Province, China.
World J Gastroenterol. 2019 Jul 21;25(27):3590-3606. doi: 10.3748/wjg.v25.i27.3590.
Obesity is a major risk factor for a variety of diseases such as diabetes, nonalcoholic fatty liver disease, and cardiovascular diseases. Restricting energy intake, or caloric restriction (CR), can reduce body weight and improve metabolic parameters in overweight or obese patients. We previously found that Lingguizhugan decoction (LZD) in combination with CR can effectively lower plasma lipid levels in patients with metabolic syndrome. However, the mechanism underlying CR and LZD treatment is still unclear.
To investigate whether CR and LZD improve metabolic parameters by modulating gut microbiota.
We extracted the water-soluble components out of raw materials and dried as LZD extracts. Eight-week old male C57BL/6 mice were treated with a 3-d treatment regime that included 24 h-fasting followed by gavage of LZD extracts for 2 consecutive days, followed by a normal diet (ND) for 16 wk. To test the effects of gut microbiota on diet-induced obesity, 8-wk old male C57BL/6 mice received fecal microbiota transplantation (FMT) from CR and LZD-treated mice every 3 d and were fed with high-fat diet (HFD) for 16 wk. Control mice received either saline gavage or FMT from ND-fed mice receiving saline gavage as mentioned above. Body weight was monitored bi-weekly. Food consumption of each cage hosting five mice was recorded weekly. To monitor blood glucose, total cholesterol, and total triglycerides, blood samples were collected submandibular bleeding after 6 h fasting. Oxygen consumption rate was monitored with metabolic cages. Feces were collected, and fecal DNA was extracted. Profiles of gut microbiota were mapped by metagenomic sequencing.
We found that CR and LZD treatment significantly reduced the body weight of mice fed with ND (28.71 ± 0.29 28.05 ± 0.15, < 0.05), but did not affect plasma total cholesterol or total triglyceride levels. We then transplanted the fecal microbiota collected from CR and LZD-treated mice under ND feeding to HFD-fed mice. Intriguingly, transplanting the mice with fecal microbiota from CR and LZD-treated mice potently reduced body weight (44.95 ± 1.02 40.53 ± 0.97, < 0.001). FMT also reduced HFD-induced hepatosteatosis, in addition to improved glycemic control. Mechanistic studies found that FMT increased OCR of the mice and suppressed the expression and protein abundance of lipogenic genes in the liver. Metagenomic analysis revealed that HFD drastically altered the profile of gut microbiota, and FMT modified the profile of the gut microbiota.
Our study suggests that CR and LZD improve metabolic parameters by modulating gut microbiota.
肥胖是多种疾病的主要危险因素,如糖尿病、非酒精性脂肪肝疾病和心血管疾病。限制能量摄入,即热量限制(CR),可以减轻超重或肥胖患者的体重并改善代谢参数。我们之前发现灵龟护肝汤(LZD)联合 CR 可以有效降低代谢综合征患者的血浆脂质水平。然而,CR 和 LZD 治疗的机制尚不清楚。
研究 CR 和 LZD 是否通过调节肠道微生物群来改善代谢参数。
我们从原料中提取水溶性成分并干燥为 LZD 提取物。8 周龄雄性 C57BL/6 小鼠接受为期 3 天的处理方案,包括 24 小时禁食,随后连续 2 天灌胃 LZD 提取物,然后进行 16 周的正常饮食(ND)。为了测试肠道微生物群对饮食诱导肥胖的影响,8 周龄雄性 C57BL/6 小鼠每隔 3 天接受来自 CR 和 LZD 处理小鼠的粪便微生物群移植(FMT),并接受高脂肪饮食(HFD)16 周。对照小鼠接受生理盐水灌胃或来自接受生理盐水灌胃的 ND 喂养小鼠的 FMT,如前所述。每周监测体重。每周记录每个饲养五只小鼠的笼子的食物摄入量。为了监测血糖、总胆固醇和总甘油三酯,在禁食 6 小时后通过颌下采血收集血样。用代谢笼监测耗氧量。收集粪便并提取粪便 DNA。通过宏基因组测序绘制肠道微生物群图谱。
我们发现 CR 和 LZD 治疗显著降低了 ND 喂养的小鼠体重(28.71±0.29 vs. 28.05±0.15,<0.05),但不影响血浆总胆固醇或总甘油三酯水平。然后,我们将来自 CR 和 LZD 处理小鼠的粪便微生物群移植到 HFD 喂养的小鼠中。有趣的是,移植来自 CR 和 LZD 处理小鼠的粪便微生物群的小鼠体重明显减轻(44.95±1.02 vs. 40.53±0.97,<0.001)。FMT 还改善了血糖控制,同时减轻了 HFD 诱导的肝脂肪变性。机制研究发现,FMT 增加了小鼠的 OCR,并抑制了肝脏中脂肪生成基因的表达和蛋白丰度。宏基因组分析显示,HFD 极大地改变了肠道微生物群的特征,FMT 改变了肠道微生物群的特征。
我们的研究表明,CR 和 LZD 通过调节肠道微生物群来改善代谢参数。